Company profile for Norgine

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Our commitment to transforming people's lives drives everything we do and our European experience, fully integrated infrastructure and exceptional partnership approach enables us to quickly apply creative solutions to bring life-changing medicines to patients that they may not otherwis...
Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Our commitment to transforming people's lives drives everything we do and our European experience, fully integrated infrastructure and exceptional partnership approach enables us to quickly apply creative solutions to bring life-changing medicines to patients that they may not otherwise be able to access. Norgine is proud to have helped 22 million patients around the world in 2019 and generated €419 million in net product sales, a growth of 6% over 2018.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Netherlands
Address
Address
Norgine BV Antonio Vivaldistraat 150 1083 HP Amsterdam
Telephone
Telephone
+31 20 567 0900
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/norgine-completes-acquisition-of-theravia-302529332.html

PR NEWSWIRE
14 Aug 2025

https://www.prnewswire.com/news-releases/swissmedic-approves-ifinwil-eflornithine-for-children-diagnosed-with-high-risk-neuroblastoma-hrnb-302499271.html

PR NEWSWIRE
09 Jul 2025

https://www.prnewswire.com/news-releases/norgine-welcomes-tga-registration-in-australia-of-ifinwil-eflornithine-for-adults-and-children-diagnosed-with-high-risk-neuroblastoma-hrnb1-302430883.html

PR NEWSWIRE
17 Apr 2025

https://www.prnewswire.com/news-releases/norgine-strengthens-rare-disease-portfolio-with-acquisition-of-theravia-302427963.html

PR NEWSWIRE
15 Apr 2025

https://www.prnewswire.com/news-releases/x4-pharmaceuticals-announces-ema-validation-of-marketing-authorization-application-maa-for-mavorixafor---licenced-to-norgine-for-commercialisation-in-europe-302359812.html

PR NEWSWIRE
24 Jan 2025

https://www.globenewswire.com/news-release/2025/01/13/3008383/0/en/X4-Pharmaceuticals-and-Norgine-Enter-into-Exclusive-Licensing-Agreement-to-Commercialize-Mavorixafor-in-Europe-Australia-and-New-Zealand.html

GLOBENEWSWIRE
13 Jan 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty